

Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses

William W. Reiley,¹ Wei Jin,¹ Andrew Joon Lee,¹ Ato Wright,¹ Xuefeng Wu,¹ Eric F. Tewalt,¹ Timothy O. Leonard,² Christopher C. Norbury,¹ Leo Fitzpatrick,³ Mingying Zhang,¹ and Shao-Cong Sun¹

¹Department of Microbiology and Immunology, ²Department of Pathology, and ³Department of Surgery, Pennsylvania State University College of Medicine, Hershey, PA 17033

The deubiquitinating enzyme CYLD has recently been implicated in the regulation of signal transduction, but its physiological function and mechanism of action are still elusive. In this study, we show that CYLD plays a pivotal role in regulating T cell activation and homeostasis. T cells derived from *Cyld* knockout mice display a hyperresponsive phenotype and mediate the spontaneous development of intestinal inflammation. Interestingly, CYLD targets a ubiquitin-dependent kinase, transforming growth factor- β -activated kinase 1 (Tak1), and inhibits its ubiquitination and autoactivation. *Cyld*-deficient T cells exhibit constitutively active Tak1 and its downstream kinases c-Jun N-terminal kinase and I κ B kinase β . These results emphasize a critical role for CYLD in preventing spontaneous activation of the Tak1 axis of T cell signaling and, thereby, maintaining normal T cell function.

CORRESPONDENCE

Shao-Cong Sun:
sxs70@psu.edu

Abbreviations used: DUB, deubiquitinating enzyme; EMSA, electrophoresis mobility shift assay; ERK, extracellular-regulated kinase; GST, glutathione *S*-transferase; IB, immunoblotting; IBD, inflammatory bowel disease; IKK, I κ B kinase; IP, immunoprecipitation; JNK, c-Jun N-terminal kinase; Tak1, TGF- β -activated kinase 1.

T cells serve as a central component of the adaptive immune system. A defect in T cell activation results in severe immune deficiencies, whereas deregulated T cell activation is associated with chronic inflammations and autoimmunity (1). Thus, the process of T cell activation is subject to tight regulation by positive and negative mechanisms. One recently discovered mechanism of T cell regulation is ubiquitination, which plays an important role in both the development and activation of T cells (2). Protein ubiquitination is a reversible process that is counter-regulated by ubiquitin-conjugating enzymes and deubiquitinating enzymes (DUBs; reference 3). Although the ubiquitin-conjugating enzymes have been extensively studied, little is known about how the DUBs participate in immune regulation, particularly in the regulation of T cell function. We have recently shown that a DUB, CYLD, regulates TCR-proximal signaling in thymocytes and is required for thymocyte development (4), although its role in peripheral T cell function is enigmatic.

CYLD was originally identified as a tumor suppressor that is mutated in familial cylindromatosis (5). Because patients carry a heterozygous mutation of the *Cyld* gene with a loss of heterozygosity occurring only in tumor cells, the physiological function of CYLD was not resolved by the patient studies. The DUB function of CYLD was first revealed by in vitro work showing that CYLD inhibits the ubiquitination of certain TNF receptor-associated factors and the regulatory subunit of I κ B kinase ([IKK] IKK γ ; references 6–8). When transfected in cell lines, CYLD inhibits the activation of NF- κ B and mitogen-activated protein kinases stimulated by innate immune receptors, such as the Toll-like receptors and TNF receptors (6–11). However, recent studies using *Cyld* knockout (*Cyld*^{-/-}) mice suggest that the signaling function of CYLD is complex and may vary among different cell types and stimulation conditions (4, 12, 13). As such, it is still not clear how CYLD regulates NF- κ B and other signaling pathways under physiological conditions.

NF- κ B represents a family of transcription factors that plays a central role in regulating the activation and homeostasis of T cells (14).

W. W. Reiley and W. Jin contributed equally to this paper.

The online version of this article contains supplemental material.

Supplemental material can be found at:
<http://doi.org/10.1084/jem.20062694>

The NF- κ B factors are normally sequestered in the cytoplasm through physical interaction with inhibitory proteins, predominantly I κ B α (15). Activation of NF- κ B by diverse immunologic stimuli typically involves the degradation of I κ B α , which, in turn, is triggered through I κ B α phosphorylation by the IKK (15). IKK is composed of two catalytic subunits, IKK α and IKK β , and a regulatory subunit termed IKK γ or NF- κ B essential modulator. IKK β plays the primary role in mediating the canonical pathway of NF- κ B activation, whereas IKK α regulates an alternative pathway involving processing of the NF- κ B2 precursor protein p100 (15–17).

Cross-linking of the TCR and CD28 costimulatory molecule in T cells leads to activation of the canonical NF- κ B pathway; this signaling cascade involves several intermediate molecules, including CARMA1, Bcl10, and MALT1 (14). Recent genetic evidence suggests that IKK activation by the TCR signal requires TGF- β -activated kinase 1 (Tak1; references 18–20), a ubiquitin-dependent kinase (21) known to phosphorylate and activate IKK β (22). In addition to activating IKK, Tak1 also mediates the TCR-stimulated activation of c-Jun N-terminal kinase (JNK; references 18–20). These findings suggest that Tak1 is a master kinase that mediates the activation of both IKK and JNK, although how Tak1 is regulated in T cells remains elusive. We show in this study that CYLD physically interacts with Tak1 and inhibits its ubiquitination and catalytic activity. The loss of CYLD in T cells results in the constitutive activation of Tak1 and

its downstream kinases JNK and IKK β . Consistently, the *Cyld*^{-/-} T cells display a hyperresponsive phenotype and mediate the spontaneous development of intestinal inflammation in *Cyld*^{-/-} mice. These findings establish CYLD as a specific DUB that prevents spontaneous activation of the Tak1 axis of TCR signaling and, thereby, maintains normal T cell responses.

RESULTS

***Cyld*-deficient T cells are hyperresponsive to TCR stimulation in vitro**

To examine how CYLD regulates peripheral T cell activation, we began by analyzing the activation of *Cyld*^{-/-} T cells in vitro. Interestingly, the loss of CYLD resulted in the hyperproliferation of lymph node T cells when stimulated with agonistic anti-CD3 and -CD28 antibodies (Fig. 1 A). Compared with the wild-type T cells, the *Cyld*^{-/-} T cells also produced markedly larger amounts of cytokines, including IFN- γ (Fig. 1 B) and IL-2 (Fig. 1 C). Similar results were obtained with splenic T cells (Fig. S1, available at <http://www.jem.org/cgi/content/full/jem.20062694/DC1>). To determine whether the hyperresponsive phenotype of *Cyld*^{-/-} T cells occurred in the naive or memory population, we purified these cells by flow cytometric cell sorting. Remarkably, the loss of CYLD resulted in hyperproliferation and aberrant cytokine production in both naive and memory T cells (Fig. 1, D and E). These results suggest a pivotal role for CYLD in negatively regulating peripheral T cell activation.




Figure 1. Hyperresponsiveness of *Cyld*^{-/-} T cells. (A–C) Wild-type (+/+) and *Cyld*^{-/-} mesenteric lymph node T cells were either not treated (NT) or were stimulated with the indicated amounts of plate-bound anti-CD3 plus soluble anti-CD28. Cell proliferation (A) and cytokine production (B and C) were measured by thymidine incorporation and ELISA, respectively. Data are presented as means \pm SD (error bars) of three independent experiments.

(D and E) Purified naive and memory T cells were stimulated with plate-bound anti-CD3 (2.5 μ g/ml for naive and 1 μ g/ml for memory T cells) and anti-CD28 (2.5 μ g/ml for naive and 1 μ g/ml for memory T cells) for 48 h followed by measuring cell proliferation and IFN- γ production as in A and B.

Cyld^{-/-} mice spontaneously develop autoimmune symptoms and colonic inflammation

Because abnormal T cell responses are often associated with chronic inflammations and autoimmunity (1), we examined whether *Cyld*^{-/-} mice develop immunological abnormalities. Even at early ages (8 wk), the *Cyld*^{-/-} mice exhibited prominent lymphocyte infiltration into the periportal region of the liver (Fig. 2 A). More prominently, the colons of the *Cyld*^{-/-} mice contained markedly more and larger lymphoid follicles or colonic patches (Fig. 2 B, bottom; arrows). Colonic patch hypertrophy is a hallmark of hapten-induced colitis and is implicated in the development of inflammation in human inflammatory bowel disease (IBD; reference 23). Of note, the lymphocytes from the colonic patches often breached into the mucosal layer and were associated with crypt damage and focal architectural distortion (Fig. 2 B, bottom; arrows). Moreover, as seen in animal models of IBD and human IBD,

inflammatory cell infiltration was also detected in the lamina propria of the colon in areas that lack the colonic patches (Fig. 2 C, arrow 1). Crypt damage (Fig. 2 C, arrow 2) and thickening of the muscularis layer (Fig. 2 C, arrow 3) were also readily detected in these inflamed areas. Consistent with the involvement of CD4 T cells in IBD, we detected abundant infiltrating CD4 T cells in both the colonic patches and the inflamed mucosa (Fig. 2 D). These IBD-like pathological phenotypes were not detected in the control mice (Fig. 2, A–D). Indeed, blind analyses of the colonic sections revealed that the *Cyld*^{-/-} mice had substantially higher IBD histological scores than the background scores of their wild-type littermates (Fig. 2 E).

A molecular hallmark of IBD is the expression of pro-inflammatory mediators in the colon, which contributes to inflammation and destruction of the colonic tissue (24). To further examine the similarity between the intestinal inflammation




Figure 2. Spontaneous development of autoimmune symptoms and colonic inflammation in *Cyld*^{-/-} mice. (A–C) Hematoxylin-eosin staining of tissue sections of the liver (A) and the distal portion of the colon (B and C) from 8-wk-old control (+/+) and *Cyld*^{-/-} mice. Inflammatory cell infiltration in the periportal vein of the liver (A), colonic patches in the colon (B; arrows), and inflammatory cell infiltration in the colonic mucosa (C; arrow 1) are indicated. In C, arrows 2 and 3 indicate crypt damage and muscularis layer thickening, respectively. (D) Immunohistochemistry staining of colon sections with anti-CD4 showing massive CD4 T cell infiltration in the *Cyld*^{-/-} colon. Data in A–D are representative of four different experiments, each with four wild-type and four *Cyld*^{-/-} mice. (E) Histological scores of mucosal inflammation in wild-type and *Cyld*^{-/-} mice. Data were obtained from three wild-type and three *Cyld*^{-/-} mice (8 wks of age), each with two colon sections. Similar results were obtained

from three additional experiments. (F) RNase protection assay showing the constitutive expression of several proinflammatory genes in the colon of *Cyld*^{-/-} mice (#1 and #3) but not wild-type mice (#2 and #4). The housekeeping genes *L32* and *Gapdh* were included as loading controls. (G) Body weight of wild-type and *Cyld*^{-/-} mice showing the reduced body weights of male and female *Cyld*^{-/-} mice (8 wks old). *, $P < 0.05$. (H) Adjacent localization of *Cyld* and *NOD2* genes on human chromosome 16. The nucleotide number was based on the sequence of *Homo sapiens* chromosome 16 clone RP11-327F22 (GenBank/EMBL/DBJ accession no. AC007728). The map was drawn to scale, and the transcriptional direction of the genes is indicated by arrows. Note that the two genes have the same transcriptional direction and are separated by only 8,988 nucleotides. Error bars represent SD. Bars (A and D), 200 μm ; (B) 500 μm ; (C) 400 μm .

of *Cyld*^{-/-} mice and IBD, we analyzed cytokine gene expression in the colons of *Cyld*^{-/-} and wild-type mice. The constitutive expression of several proinflammatory genes was detected in the colons of *Cyld*^{-/-} mice but not in the colons of wild-type mice (Fig. 2 F). The *Cyld*^{-/-} mice also expressed larger amounts of T cell–derived cytokines, including IL-4 and -12 (Fig. 2 F). The level of an antiinflammatory cytokine, IL-10, was moderately enhanced in the *Cyld*^{-/-} colon (Fig. S2 A, available at <http://www.jem.org/cgi/content/full/jem.20062694/DC1>). The elevated expression of IL-10 has also been detected in other models of mouse colitis as well as in human IBD patients (25–27), although the underlying functional significance in IBD pathogenesis is unclear. Nevertheless, our results suggest that the intestinal inflammation in *Cyld*^{-/-} mice is associated with the aberrant expression of proinflammatory cytokines. In addition to the histological and biochemical features of IBD, the *Cyld*^{-/-} mice had substantial weight loss (Fig. 2 G), a characteristic clinical symptom of IBD patients (28). Of note, these results were obtained with mice housed under pathogen-free conditions with wild-type littermates being used as controls. Thus, the *Cyld*^{-/-} mice develop spontaneous colonic inflammation and extraintestinal abnormalities that resemble IBD.

By analyzing the human genome sequence, we found that the human *Cyld* gene is located in a major IBD susceptibility locus (IBD-1) on chromosome 16 adjacent to a known IBD regulatory gene, *NOD2* (Fig. 2 H). This finding suggests an intriguing possibility that CYLD may also be involved in the regulation of human IBD.

Adoptive transfer of *Cyld*^{-/-} T cells induces autoimmune symptoms and colonic inflammation in recipient mice

Given the hyperresponsive phenotype of *Cyld*^{-/-} T cells, it was important to examine whether these mutant T cells contribute to the development of IBD-like symptoms. We adoptively transferred T cells from either *Cyld*^{-/-} or wild-type mice into *RAG1*^{-/-} mice that lack endogenous lymphocytes. The *RAG1*^{-/-} recipients of both *Cyld*^{-/-} and wild-type T cells had an efficient T cell repopulation in the spleen 6 wk after the adoptive transfer (Fig. 3 A). However, the *RAG1*^{-/-} recipients of *Cyld*^{-/-} T cells but not those of wild-type T cells displayed lymphocyte infiltration into the periportal regions of the liver (Fig. 3 B). Moreover, the *RAG1*^{-/-} recipients of *Cyld*^{-/-} T cells spontaneously developed colitis, which was characterized by inflammatory cell infiltration, thickening of the mucosa, and goblet cell depletion (Fig. 3 C). The IBD histology scores




Figure 3. Induction of autoimmunity and colitis by adoptively transferred *Cyld*^{-/-} T cells. *RAG1*^{-/-} mice (8 wks old) were intravenously injected with T cells isolated from the mesenteric lymph nodes of wild-type (+/+) or *Cyld*^{-/-} mice. (A–C) After 6 wk, the recipient mice were killed for flow cytometry analyses of transferred T cells in the spleen (A), histology analyses of lymphocyte infiltration in the liver (B), and inflammation of the colon (C). The numbers in A indicate the percentages of CD8 (top left quadrants) and CD4 (bottom right quadrants) T cells. An arrow in C (bottom) indicates a colonic patch detected in a recipient of

Cyld^{-/-} T cells. Data are representative of three mice per group. (D) Histology scores measuring the degree of colonic inflammation in the recipient wild-type (+/+) and *Cyld*^{-/-} T cells. Data were obtained from three mice per group. (E) Body weights of recipient mice. Body weights were measured 6 wk after T cell transfer, showing the substantial weight loss in the recipients of *Cyld*^{-/-} T cells. (F) Image to compare the colons of recipients of wild-type (+/+) and *Cyld*^{-/-} T cells. Error bars represent SD. Bars (B), 200 μm; (C) 1 mm.

of these mice were markedly higher than the background detected in recipients of wild-type T cells (Fig. 3 D). In addition to these histological features, the recipients of *Cyld*^{-/-} T cells had substantial weight loss (Fig. 3 E) and expressed high levels of proinflammatory cytokines in the colon (Fig. S2 B). Severe bowel thickening was also observed in some of the recipients of *Cyld*^{-/-} T cells but not in the controls (Fig. 3 F). These findings demonstrate that the T cells from *Cyld* knockout mice are sufficient to induce IBD-like features.

Constitutive activation of JNK and NF- κ B in *Cyld*^{-/-} T cells

To understand the molecular mechanism mediating the abnormal T cell responses in *Cyld*^{-/-} mice, we examined TCR signaling. We have previously shown that CYLD positively regulates LCK function and TCR-proximal signaling in thymocytes (4). However, because LCK is largely dispensable for peripheral T cell activation (29), it was intriguing to examine whether the loss of CYLD affected the TCR-proximal signaling of peripheral T cells. In naive T cells, the *Cyld* deficiency had no appreciable effect on the TCR/CD28-mediated phosphorylation of ZAP-70 and the mitogen-activated

protein kinase extracellular-regulated kinase (ERK; Fig. 4 A). Interestingly, in the *Cyld*^{-/-} T cells, JNK became constitutively activated (Fig. 4 A, lane 4). The constitutive activation of JNK was also detected using *Cyld*^{-/-} total T cells (unpublished data). Thus, in peripheral T cells, CYLD is not required for TCR-proximal signaling but serves as a crucial negative regulator of JNK.

To further investigate the signaling basis for the hyperresponsive property of *Cyld*^{-/-} T cells, we examined the activation of transcription factor NF- κ B. As expected, cross-linking of TCR/CD28 led to activation of the nuclear DNA-binding activity of NF- κ B (Fig. 4 B). Remarkably, as seen with JNK, high levels of active NF- κ B were detected in *Cyld*^{-/-} T cells even under unstimulated conditions (Fig. 4 B, lane 5). Of note, the constitutive activation of NF- κ B occurred in both the naive and memory *Cyld*^{-/-} T cells (Fig. 4 C), further arguing for an intrinsic role for this DUB in negatively regulating the JNK and NF- κ B signaling axes in T cells. Antibody supershift assays revealed that the constitutively activated NF- κ B complex in *Cyld*^{-/-} T cells was predominantly composed of the canonical NF- κ B members p50 and RelA (Fig. 4 D).




Figure 4. Constitutive activation of JNK and NF- κ B in *Cyld*^{-/-} T cells. (A) Purified naive lymph node T cells from control (+/+) and *Cyld*^{-/-} mice were stimulated with 1 μ g/ml anti-CD3 and 1 μ g/ml anti-CD28 for the indicated times. Immunoblotting (IB) assays were performed using the indicated phosphospecific (α -P) and pan-antibodies to determine the phosphorylation of ZAP-70, ERK, and JNK. (B) Hyperactivation of NF- κ B in *Cyld*^{-/-} T cells. Wild-type (+/+) and mutant (-/-) total lymph node T cells were stimulated with 1 μ g/ml of plate-bound anti-CD3 and 1 μ g/ml of soluble anti-CD28 for the indicated times. Nuclear extracts were subjected to EMSA to determine the activity of NF- κ B. Actin IB was included

as a loading control. (C) Nuclear extracts were isolated from purified naive and memory T cells and were subjected to EMSA to determine the constitutive activity of NF- κ B. An EMSA of NF- κ B was included as a control. (D) EMSA was performed using the nuclear extract isolated from untreated *Cyld*^{-/-} T cells in the presence of the indicated antibodies. The antibody-shifted complexes are indicated by arrows. (E) Whole cell extracts were isolated from wild-type (+/+) and *Cyld*^{-/-} mesenteric T cells and subjected to IB assays to detect the indicated NF- κ B members. (F) RT-PCR was performed to detect mRNA of *relB* and *Gapdh* using total RNA isolated from wild-type (+/+) or *Cyld*^{-/-} mesenteric lymph node cells.

Parallel immunoblotting (IB) assays revealed the markedly enhanced expression of noncanonical NF- κ B members RelB and p100 at the levels of both protein (Fig. 4 E) and RNA (Fig. 4 F and not depicted). Because the genes encoding these two proteins are regulated by NF- κ B (30, 31), this result further supported the conclusion that CYLD deficiency causes the constitutive activation of NF- κ B. We noticed that p100 remained largely unprocessed (not converted to p52; Fig. 4 E) despite its up-regulation. Because p100 is a specific inhibitor of RelB, this finding explained why RelB was not detected in the active nuclear NF- κ B complex (Fig. 4 D). Thus, the loss of CYLD is associated with the constitutive activation of canonical NF- κ B and JNK, a result that provides a mechanistic insight into the hyperresponsive phenotype of *Cyld*^{-/-} T cells.

Constitutive activation of IKK β in *Cyld*^{-/-} T cells and *Cyld* knockdown Jurkat T cells

To understand the mechanism of constitutive NF- κ B activation associated with *Cyld* deficiency, we examined the level and fate of the primary NF- κ B inhibitor I κ B α . In *Cyld*^{-/-} T cells, the steady-state level of I κ B α was substantially lower than in wild-type T cells (Fig. 5 A, top). This abnormality was not caused by reduced expression of the I κ B α gene. In

fact, the *Cyld*^{-/-} T cells expressed a markedly higher level of I κ B α mRNA than the wild-type T cells (Fig. 5 B). Interestingly, despite their lower level of total I κ B α protein, the mutant T cells had more phosphorylated I κ B α (Fig. 5 A, middle). These findings suggested that I κ B α might be undergoing chronic degradation and resynthesis in the *Cyld*-deficient T cells. Indeed, inhibition of protein synthesis by cycloheximide led to the rapid depletion of I κ B α in *Cyld*^{-/-} T cells but only had a weak effect on the I κ B α level in wild-type T cells (Fig. 5 C, compare lane 2 with lane 4). The chronic degradation of I κ B α appeared to be dependent on IKK β because this event was blocked by a selective IKK β inhibitor, PS1145 (Fig. 5 C, lane 7). Consistent with these results, the *Cyld*^{-/-} T cells displayed a high level of constitutive IKK β catalytic activity (Fig. 5 D, top; lanes 1 and 2). Thus, the loss of CYLD results in constitutive activation of the NF- κ B signaling pathway in T cells.

To determine whether the constitutive activation of IKK β occurred in naive *Cyld*^{-/-} T cells, we began by analyzing the IKK β kinase activity in thymocytes. As seen with peripheral T cells, *Cyld*^{-/-} thymocytes exhibited constitutive IKK β activity (Fig. 5 D). Next, we purified naive peripheral T cells by flow cytometric cell sorting. Because the low number of highly purified naive T cells precluded us from performing in




Figure 5. *Cyld* deficiency results in the constitutive activation of IKK β and chronic degradation of I κ B α . (A and B) Chronic degradation and resynthesis of I κ B α in *Cyld*^{-/-} T cells. Wild-type (+/+) and mutant (-/-) total T cells were subjected to IB assays (A) or RT-PCR (B) to detect the total and phosphorylated I κ B α (P-I κ B α) and the I κ B α messenger RNA, respectively. (C) I κ B α degradation in *Cyld*^{-/-} T cells is mediated by IKK β . Wild-type and mutant T cells were incubated for 50 min in the absence (-) or presence (+) of 10 μ g/ml cycloheximide (CHX). In lane 7, the cells were preincubated with 10 μ M of the IKK β inhibitor PS1145 for 60 min before the start of cycloheximide treatment. The expression of I κ B α as well as CYLD and tubulin was analyzed by IB. (D) Chronic activation of

IKK β in *Cyld*^{-/-} T cells. IKK β was isolated by immunoprecipitation (IP; using anti-IKK β) from untreated wild-type (+/+) and *Cyld*^{-/-} lymph node T cells and thymocytes, and the activity of IKK β was measured by in vitro kinase assays using both GST-I κ B α and GST-IKK β substrates (top two panels). IB was performed to monitor the IKK β protein level (bottom). (E) Whole cell extracts isolated from purified naive T cells (untreated) were subjected to IB. (F) Whole cell extracts isolated from untreated Jurkat-pSUPER and Jurkat-shCYLD cells were subjected to IKK β kinase assay (KA; top) followed by IB to detect the IKK β protein on the kinase assay membrane (second blot). Cell lysates were subjected to IB to detect the indicated proteins (third to fifth blots).

vitro kinase assays, we attempted to detect the in vivo phosphorylation of IKK β based on its band shift on SDS gels. Indeed, when fractionated on a low-percentage gel, IKK β exhibited a clear band shift in *Cyld*^{-/-} but not control naive T cells (Fig. 5 E). Consistently, the naive T cells had a reduced level of I κ B α and an up-regulated level of RelB and p100 (Fig. 5 E). Thus, IKK β is chronically activated in naive T cells of *Cyld*^{-/-} mice.

We next used an alternative approach to confirm that the loss of CYLD in T cells causes the constitutive activation of IKK β . By infecting Jurkat T cells with a retroviral vector encoding a *Cyld*-specific small hairpin RNA (shCYLD), we were able to generate a bulk of cells with a greatly reduced level of CYLD (Fig. 5 F, bottom). As seen with the primary T cells, the *Cyld* knockdown Jurkat cells displayed the hyperactivation of IKK β (Fig. 5 F, top), and this abnormality was associated with the reduction in I κ B α protein level (Fig. 5 F, third blot). Collectively, these results suggest that CYLD plays a crucial role in preventing the spontaneous activation of IKK β or its upstream signaling steps.

CYLD controls the activity of Tak1

The involvement of CYLD in the regulation of both JNK and IKK β suggests a role for this DUB in controlling the activity of a more upstream molecule. However, because *Cyld* deficiency did not cause the activation of ERK, the target of CYLD might be an intermediate signaling factor specifically mediating the activation of JNK and IKK β . In this regard, recent genetic studies highlighted a critical role for Tak1 in mediating the TCR-stimulated activation of IKK and JNK (18–20). Therefore, we examined whether Tak1 is under the control of CYLD. Indeed, the high constitutive activity of Tak1 was detected in both peripheral T cells and thymocytes of *Cyld*^{-/-} mice (Fig. 6 A). Moreover, RNAi-mediated *Cyld* knockdown in Jurkat T cells also resulted in the constitutive activation of Tak1 (Fig. 6 A). These results establish a pivotal role for CYLD in controlling Tak1 function and explain how CYLD negatively regulates IKK β and JNK.

Previous in vitro studies suggest that Tak1 is a ubiquitin-dependent kinase (21). Although how the catalytic activity of Tak1 is regulated in vivo is not well understood, a recent study suggests that the polyubiquitination of Tak1 mediates its autoactivation (32). Thus, it was logical to examine whether CYLD targets Tak1 and regulates its ubiquitination. Interestingly, endogenous CYLD and Tak1 indeed formed a complex in T cells, which was readily detected by co-immunoprecipitation (IP) assays using the anti-CYLD antibody (Fig. 6 B). This molecular interaction was specific because Tak1 was not precipitated by anti-CYLD from the *Cyld*^{-/-} T cells (Fig. 6 B, lane 2). Specific CYLD–Tak1 interaction was also readily detected in transfected cells (Fig. 6 C). To determine whether Tak1 is a functional target of CYLD, we analyzed the effect of CYLD on Tak1 ubiquitination. As expected (32), transfected Tak1 underwent constitutive polyubiquitination (Fig. 6 D). Importantly, the ubiquitination of Tak1 was efficiently inhibited by CYLD. Furthermore,

consistent with the constitutive Tak1 activation in *Cyld*^{-/-} T cells, transfected CYLD potently suppressed the catalytic activity of Tak1 (Fig. 6 E).

To further assess the role of CYLD in regulating Tak1 ubiquitination, we analyzed the ubiquitination of endogenous Tak1. Remarkably, the loss of CYLD resulted in a considerable elevation of Tak1 ubiquitination in T cells (Fig. 6 F), thus providing evidence for the involvement of CYLD in modulating Tak1 ubiquitination in vivo. We also analyzed the effect of *Cyld* deficiency on the ubiquitination of IKK γ because this molecular event can be inhibited by transfected CYLD (6–8). A considerable basal level of IKK γ ubiquitination was detected in wild-type T cells, which was moderately enhanced in *Cyld*^{-/-} T cells (Fig. 6 F). Thus, Tak1 appears to be a primary target of CYLD in T cells, although the involvement of CYLD in regulating other signaling components of the NF- κ B pathway cannot be excluded.

DISCUSSION

In this study, we demonstrate a critical role for CYLD in controlling the catalytic activity of Tak1 and its downstream kinases in T cells. This function of CYLD was demonstrated using different cell systems: total T cells, naive T cells, and *Cyld* knockdown Jurkat T cells. Consistently, the *Cyld*^{-/-} T cells are hyperresponsive to TCR/CD28 stimulation, and the *Cyld*^{-/-} mice spontaneously develop intestinal inflammation. Furthermore, the adoptive transfer of *Cyld*^{-/-} T cells into RAG1 knockout mice is sufficient to induce the inflammatory phenotype, thus suggesting that the abnormal response of T cells in *Cyld*^{-/-} mice plays a primary role in the spontaneous development of intestinal inflammation.

Genetic and biochemical evidence has established Tak1 as a pivotal kinase that mediates the activation of IKK and JNK by diverse cellular stimuli (18–20, 22, 33–35). Using T cell-specific Tak1 knockout mice, several groups have recently shown that Tak1 is required for the TCR-stimulated activation of IKK and JNK and T cell development (18–20). Because of the lack of Tak1-deficient peripheral T cells in these mutant animals, the signaling function of Tak1 in naive T cells could not be assessed. In vitro deletion of Tak1 in preactivated T cells (similar to effector T cells) indicates that it is essential for JNK activation but functionally redundant for IKK activation under these conditions (20). Despite the potential variations in the necessity of Tak1, its potent activity in IKK/JNK activation suggests the requirement for a tight mechanism of regulation. Our data emphasize a critical role for CYLD in Tak1 regulation. The loss of CYLD in both primary T cells and the Jurkat T cell line causes the constitutive activation of Tak1 as well as its downstream targets JNK and IKK. Because ERK is not affected by the *Cyld* deficiency, it is unlikely that CYLD negatively regulates a further upstream component in the TCR signaling pathway. Indeed, our data suggest that CYLD directly targets Tak1 and inhibits Tak1 ubiquitination. In keeping with a previous finding that Tak1 ubiquitination mediates its autoactivation (32), we have shown that CYLD potently inhibits the catalytic activity of




Figure 6. CYLD physically interacts with Tak1 and inhibits the ubiquitination and autoactivation of Tak1. (A) Tak1 was isolated by IP from lymph node T cells, thymocytes, or Jurkat T cells followed by kinase assays (KA) using recombinant MKK6 as a substrate (top). The kinase assay membrane was further subjected to IB to detect the Tak1 protein (bottom). (B) The CYLD complex was isolated by IP from wild-type (+/+) or *Cyld*^{-/-} thymocytes followed by IB to detect CYLD and its associated Tak1. The Tak1 level in cell lysates was monitored by IB (bottom). (C) 293 cells were transfected with 150 ng CYLD either in the absence (-) or presence (+) of 100 ng Tak1. The Tak1 complex was isolated by IP followed by IB to detect Tak1 and associated CYLD. The CYLD expression level was analyzed by IB (bottom). (D) 293 cells were transfected with 100 ng Tak1 either in the absence (-) or presence (+) of CYLD (150 ng in lane 3 and 300 ng in lane 4) along with 200 ng hemagglutinin (HA)-tagged ubiquitin. Tak1 was

isolated by IP followed by IB (with antihemagglutinin) to examine its ubiquitin conjugation. (E) 293 cells were transfected with 100 ng Tak1 in the absence (-) or presence (+) of two doses of CYLD (150 and 300 ng). The cells were also transfected with 100 ng of the Tak1 partner protein Tab1. Tak1 was isolated by IP followed by kinase assays using recombinant MKK6 as substrate (top). The kinase assay membrane was further subjected to IB to detect the precipitated Tak1 (middle). CYLD expression in lysates was monitored by IB (bottom). (F) Tak1 and IKK γ were isolated by IP from wild-type (+/+) and CYLD-deficient (-/-) T cells and were subjected to IB (using antiubiquitin) to detect the ubiquitinated Tak1 and IKK γ . The membrane was reprobed with anti-Tak1 to monitor the precipitated Tak1 protein (bottom). Because IKK γ comigrates with the Ig heavy chain, direct IB was performed to monitor its expression level (bottom).

Tak1 in transfected cells. Thus, CYLD has a pivotal role in preventing the spontaneous activation of Tak1 and its downstream kinases JNK and IKK.

Previous studies suggest that A20 is a DUB that functions to prevent the prolonged activation of IKK in innate immune cells (36–38). To understand the functional difference between CYLD with A20, we examined whether CYLD regulates the kinetics or magnitude of the signal-induced activation of IKK β in innate immune cells. Surprisingly, the loss of CYLD did not result in the basal activation of IKK β or Tak1 in macrophages (Fig. S3, A and B, available at <http://www.jem.org/cgi/content/full/jem.20062694/DC1>). This result suggests a cell type-specific function of CYLD or functional redundancy of CYLD with other DUBs in certain cell types such as macrophages. The *Cyld* deficiency also did not alter the level of the LPS-stimulated activation of IKK β or prolong the activation of IKK β after an extended time course of LPS stimulation (Fig. S3 C). Thus, unlike A20 (37), CYLD does not play an essential role in controlling the basal or inducible activation of IKK β in macrophages. Another major difference between CYLD and A20 is that CYLD does not seem to play a role in turning off the inducible IKK activation. Despite its essential role in suppressing the constitutive activity of IKK β in T cells, the loss of

CYLD in Jurkat T cells did not appreciably prolong the IKK activation induced by TNF- α or mitogens (Fig. S4 A, available at <http://www.jem.org/cgi/content/full/jem.20062694/DC1>). Consistently, the level of CYLD protein was not enhanced by the mitogens (Fig. S4 B) or TNF- α (not depicted). Thus, whereas A20 regulates the kinetics of inducible IKK activation in innate immune cells, CYLD is critical for regulating the spontaneous (and probably initially inducible) activation of Tak1 and IKK in T cells.

We have previously shown that CYLD positively regulates the late stage of thymocyte development (4). CYLD physically interacts with LCK and facilitates the binding of active LCK to its target ZAP-70, thereby enhancing the TCR-induced tyrosine phosphorylation of ZAP-70. We found in this study that the naive *Cyld*^{-/-} peripheral T cells did not show a defect in TCR-proximal signaling. This finding is consistent with a previous study that LCK is required for thymocyte development but is largely dispensable for peripheral T cell activation (29). Thus, the constitutive activation of Tak1 coupled with the diminished effect of CYLD on TCR-proximal signaling contributes to the hyperresponsive phenotype of *Cyld*^{-/-} T cells. Because Tak1 is also activated in *Cyld*^{-/-} thymocytes, a question is raised with regard to its

effect on thymocyte development. Based on the results of Tak1 knockout studies (18–20), the activation of Tak1 should promote thymocyte development. However, the *Cyld*^{-/-} mice even produce reduced numbers of mature thymocytes (4). Although this phenotype is clearly caused by the attenuation of LCK function and TCR-proximal signaling, it is also likely that the constitutive activation of Tak1 may contribute to the thymocyte defect by causing excessive negative selection. Future studies will examine this possibility by crossing *Cyld*^{-/-} mice with TCR transgenic mice.

One surprising finding with the Tak1 conditional knockout mice (Tak1^{flox/flox}) was their spontaneous development of intestinal inflammation at old ages despite the critical role for Tak1 in NF-κB activation (19, 20). However, this phenotype has been attributed to the requirement of Tak1 in regulatory T cell (T reg cell) development. The Tak1^{flox/flox} mice produce a scarce number of peripheral T cells, which turn out to be leaked cells that have escaped from Cre-mediated Tak1 locus deletion (19). Thus, the effector T cells that mediate inflammation are actually Tak1-expressing cells activated as a result of the lack of T reg cells (19). In contrast, the T cell abnormality of *Cyld*^{-/-} mice is intrinsic to the mainstream (responder) T cells. Both naive and memory *Cyld*^{-/-} T cells are hyperresponsive to TCR/CD28 stimulation, and the adoptively transferred T cells mediate colitis in *RAG1*^{-/-} mice. Furthermore, our preliminary studies did not detect any defect in T reg cell development in *Cyld*^{-/-} mice (unpublished data). Thus, the loss of T reg cell function or abnormality in responder T cells may contribute to the development of intestinal inflammation.

The spontaneous development of the colonic inflammation of *Cyld*^{-/-} mice suggests the intriguing possibility that CYLD may serve as an important regulator of IBD. A recent study reveals that *Cyld*^{-/-} mice are also more sensitive to dextran sodium sulfate-induced colitis (13). In addition to colonic inflammation, we have shown that the *Cyld*^{-/-} mice display other features of IBD, such as weight loss, lymphocyte infiltration into the liver, and early onset of inflammatory symptoms. In concert with the animal studies, the *Cyld* gene is located within a major IBD susceptibility locus (Fig. 2 G). This locus, IBD-1, also contains the *NOD2* gene that encodes an intracellular pattern recognition molecule that is known to mediate NF-κB activation in macrophages and intestinal epithelial cells (39). Genetic mutations of the human *NOD2* gene increase the risk of, but are insufficient for, developing IBD (40, 41). Consistently, ablation or mutation of the *NOD2* gene in mice does not cause spontaneous intestinal inflammation (42–44), although the *NOD2* mutation sensitizes mice to dextran sodium sulfate-induced intestinal inflammation (44). These findings suggest the involvement of specific environmental factors or secondary genetic factors for the development of IBD in patients carrying the *NOD2* gene mutations.

Notably, the *Cyld* gene is located adjacent to the *NOD2* gene (Fig. 2 G). At least in mice, the loss of CYLD has no effect on the expression of *NOD2* (Fig. S5, available at <http://www.jem.org/cgi/content/full/jem.20062694/DC1>). It remains

to be examined whether mutations in the *Cyld* gene occur in some of the IBD patients who are epidemiologically linked with the IBD1 locus. Because the *NOD2* gene is located immediately upstream of the *Cyld* gene, it is also possible that certain genetic mutations located at the 3' region of the *NOD2* gene may affect the expression of the *Cyld* gene. Although these possibilities need to be examined by further studies, a recent study does suggest the association of human IBD with the reduced expression of CYLD (45). Given that *NOD2* and CYLD regulate the innate and adaptive immune responses, respectively, it is intriguing to examine whether the combined genetic mutations of these two genes have a synergistic effect on the development of colitis in mice.

MATERIALS AND METHODS

Mice. *Cyld* knockout mice (in a C57BL6/DBA genetic background) were generated as described previously (4). *Cyld*^{+/-} mice were intercrossed to generate *Cyld*^{-/-} and *Cyld*^{+/+} littermates. Genotyping was performed by PCR using tail DNA and the following primers: *Cyld* forward primer, CCAGGCACTTTGAATTGCTGTC; *Cyld* reverse primer 1, CGTTC-TCCCAGTAGGGTGAAG; and *Cyld* reverse primer, GCATGCTCCAG-ACTGCCTTGG. When the three primers were used together, the PCR yielded a 209-bp product for *Cyld*^{+/+} mice, a 209- and 255-bp product for *Cyld*^{+/-} mice, and a 255-bp product for *Cyld*^{-/-} mice.

RAG1^{-/-} mice (in a C57BL6 genetic background) were purchased from Taconic. All mice were housed in specific pathogen-free cages and monitored periodically (every 3 mo) for the lack of common pathogens. Animal experiments were performed in accordance with protocols approved by the Pennsylvania State University College of Medicine Institutional Animal Care and Use Committee.

Plasmids, antibodies, and reagents. Glutathione S-transferase (GST)–IKKβ was constructed by cloning a cDNA fragment encoding amino acids 166–197 of human IKKβ into the pGex-4T-3 vector (GE Healthcare). pCMV-hemagglutinin-Tak1 and pCMV-flag-Tab1 were provided by K. Matsumoto (Nagoya University, Nagoya, Japan; reference 46). Anti-mouse CD3e (145–2C11), anti-mouse CD28, anti-CD4-PE-CY5.5 (L3T4), anti-CD44-FITC (IM7), and anti-CD25-PE (PC61.5) were purchased from eBioscience. Anti-CD19-PE-Cy7 (1D3) and other conjugated antibodies used for flow cytometric analyses and the unconjugated anti-CD4 (L3T4) were purchased from BD Biosciences. Goat anti-hamster Ig was purchased from Southern Biotechnology Associates, Inc. The anti-IKKβ (H470), anti-RelB (N-17), anti-lamin B (H-90), and anti-actin (C2) were purchased from Santa Cruz Biotechnology, Inc. Anti-ubiquitin was provided by V. Chau (Pennsylvania State College of Medicine, Hershey, PA), and anti-Tak1 was provided by K. Matsumoto and J. Ninomiya-Tsuji (North Carolina State University, Raleigh, NC). Recombinant MKK6 was purchased from Upstate Biotechnology, and cycloheximide was obtained from Sigma-Aldrich. All other antibodies and reagents have been described previously (4, 47, 48).

RNAi-mediated CYLD knockdown. Jurkat T cells were infected with either the empty pSUPER-retro-puromycin vector (Oligoengine) or the same vector encoding *Cyld* small hairpin RNA followed by puromycin selection as reported previously (48). The bulk of infected cells, named Jurkat-pSUPER and Jurkat-shCYLD, were used in experiments.

Histology and immunohistochemistry. Colons were removed from killed mice and flushed with Iscove's media. Distal and proximal halves of the colons were opened longitudinally, fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned for hematoxylin-eosin staining. Slides were analyzed blindly and scored for the degree of inflammation (0–40 scale) as described previously (49). Liver, lung, and salivary gland sections were prepared similarly, and pictures were taken from typical liver and colon sections.

For immunohistochemistry, the distal and proximal portions of colons were freshly frozen in Tissue-Tek optimal cutting temperature compound (VWR) using liquid nitrogen–prechilled 2-methylbutane. The frozen tissues were stored at -70°C until sectioning. 4–6- μm cryostat sections were prepared and stained with rat anti–mouse CD4 (eBioscience), and the bound anti–CD4 was detected by biotinylated rabbit anti–rat Ig and peroxidase–conjugated streptavidin with diaminobenzidine as chromagen (VECTASTAIN Elite ABC kit; Vector Laboratories).

Flow cytometry. Splenic and lymph node cell suspensions were prepared by gentle homogenization using a Dounce homogenizer (Wheaton). Mononuclear cells were isolated by centrifugation over lymphocyte separation media (Cellgro) and were subjected to flow cytometry analyses as previously described (4). To isolate naive and memory T cells, unfixed mesenteric lymph node cells were stained with anti–CD44–FITC, anti–CD25–PE, and anti–CD19–PE–Cy7. Naive ($\text{CD44}^{\text{lo-mcd}}\text{CD25}^{-}\text{CD19}^{-}$) and memory ($\text{CD44}^{\text{hi}}\text{CD25}^{-}\text{CD19}^{-}$) T cells were purified using a cell sorter (Moflo; DakoCytomation). The purity of the isolated populations was $>98\%$.

Cell proliferation and ELISA. Purified T cells were stimulated in five replicate wells in 96–well plates (10^5 cells/well) with the indicated amounts of plate-bound anti–CD3 and anti–CD28 (1 $\mu\text{g}/\text{ml}$). After the indicated times of stimulation, cell culture supernatants were collected and subjected to ELISA assays (eBioscience) to measure the concentration of cytokines, whereas the cells were labeled for 6 h with [^3H]thymidine for proliferation assays based on thymidine incorporation.

T cell adoptive transfer. Wild-type and *Cyld* $^{-/-}$ T cells were purified using CD90–conjugated magnetic beads (Miltenyi Biotec) from mesenteric lymph nodes, and 7×10^6 cells were injected intravenously into *RAG1* $^{-/-}$ mice. Recipient mice were monitored for weight loss and were killed after 6 wk. Colon, liver, and salivary glands were removed for histology analyses. The efficiency of adoptive transfer was assessed by flow cytometry analyses of T cells in the spleen.

Ubiquitination assays. 293 cells were transfected in 12–well plates with the indicated plasmid expression vectors. Ubiquitination of transfected and endogenous proteins was analyzed as previously described (48).

IB, electrophoresis mobility shift assay, and in vitro kinase assays. Mesenteric lymph node T cells were purified by using CD90–labeled magnetic beads and incubated on ice for 15 min with the indicated concentrations of anti–mouse CD3 and anti–mouse CD28. The cells were washed once with 500 μl of cold Iscove’s media and stimulated by cross-linking the receptor–bound anti–CD3 and –CD28 for the indicated times in a 37°C water bath with 45 $\mu\text{g}/\text{ml}$ of goat anti–hamster Ig. Jurkat cells were collected by centrifugation and resuspend in fresh media followed by stimulation with the indicated inducers. Untreated and stimulated thymocytes, lymph node T cells, and Jurkat cells were lysed in a kinase cell lysis buffer supplemented with phosphatase inhibitors and subjected to in vitro kinase assays and IB as previously described (50). For electrophoresis mobility shift assay (EMSA), thymocytes and T cells were either not treated or were stimulated with plate-bound anti–CD3 plus soluble anti–CD28 for the indicated times. Nuclear extracts were prepared and subjected to EMSA using a ^{32}P –radiolabeled κB oligonucleotide as previous described (51).

RNase protection assay and RT–PCR. Total cellular RNA was isolated from the colon using the TRI reagent (Molecular Research Center, Inc.). RNase protection assay was performed using the RiboQuant reagents (BD Biosciences) and a custom template set according to the manufacturer’s instructions. Semiquantitative RT–PCR was performed using specific primers for the indicated mouse genes.

Statistics. Statistical significance was determined by Student’s *t* test.

Online supplemental material. Fig. S1 shows the hyperresponsiveness of *Cyld* $^{-/-}$ splenic T cells, and Fig. S2 shows the enhanced expression of

inflammatory genes in colons of RAG1 knockout mice adoptively transferred with *Cyld* $^{-/-}$ T cells. Data presented in Fig. S3 suggest that the loss of CYLD does not result in the constitutive activation of IKK β and Tak1 nor affects the kinetics of inducible IKK activation in macrophages. Fig. S4 shows that CYLD is not important for turning off the IKK activation signal in Jurkat T cells. Fig S5 shows the normal expression of NOD2 in *Cyld*–deficient cells. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20062694/DC1>.

We thank Kang Li, Nate Sheaffer, and Anne Stanley of the Pennsylvania State College of Medicine core facilities for assistance with tissue sections, flow cytometry, and oligonucleotide synthesis. We also thank Vincent Chau, Kunihiro Matsumoto, and Jun Ninomiya–Tsuji for reagents.

This study was supported by grants from the National Institutes of Health (NIH; AI064639 and CA94922 to S.C. Sun, AI057555 to S.C. Sun and M. Zhang, and AI056094 to C.C. Norbury) and by an award from the Carlino Account Funds of the Section of Colon and Rectal Surgery (Pennsylvania State College of Medicine) to S.C. Sun, L. Fitzpatrick, and M. Zhang. A. Wright is a recipient of the Ruth L. Kirschstein National Research Service Award. E.F. Tewalt is a trainee of a predoctoral/postdoctoral training grant (2T32CA60395–11) from the NIH. All animals were housed in a facility constructed with support from Research Facilities Improvement (grant C06 RR–15428–01) from the National Center for Research Resources (NIH).

The authors have no conflicting financial interests.

Submitted: 22 December 2006

Accepted: 10 May 2007

REFERENCES

- Siegel, R.M., M. Katsumata, S. Komori, S. Wadsworth, L. Gill–Morse, S. Jerrold–Jones, A. Bhandoola, M.I. Greene, and K. Yui. 1990. Mechanisms of autoimmunity in the context of T–cell tolerance: insights from natural and transgenic animal model systems. *Immunol. Rev.* 118:165–192.
- Liu, Y.C. 2004. Ubiquitin ligases and the immune response. *Annu. Rev. Immunol.* 22:81–127.
- Wilkinson, K.D. 2000. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. *Semin. Cell Dev. Biol.* 11:141–148.
- Reiley, W.W., M. Zhang, W. Jin, M. Losiewicz, K.B. Donohue, C.C. Norbury, and S.C. Sun. 2006. Regulation of T cell development by the deubiquitinating enzyme CYLD. *Nat. Immunol.* 7:411–417.
- Bignell, G.R., W. Warren, S. Seal, M. Takahashi, E. Rapley, R. Barfoot, H. Green, C. Brown, P.J. Biggs, S.R. Lakhani, et al. 2000. Identification of the familial cylindromatosis tumour–suppressor gene. *Nat. Genet.* 25:160–165.
- Brummelkamp, T.R., S.M. Nijman, A.M. Dirac, and R. Bernards. 2003. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF– κB . *Nature.* 424:797–801.
- Kovalenko, A., C. Chable–Bessia, G. Cantarella, A. Israel, D. Wallach, and G. Courtis. 2003. The tumour suppressor CYLD negatively regulates NF– κB signalling by deubiquitination. *Nature.* 424:801–805.
- Trompouki, E., E. Hatzivassiliou, T. Tschirtz, H. Farmer, A. Ashworth, and G. Mosialos. 2003. CYLD is a deubiquitinating enzyme that negatively regulates NF– κB activation by TNFR family members. *Nature.* 424:793–796.
- Regamey, A., D. Hohl, J.W. Liu, T. Roger, P. Kogerman, R. Toftgard, and M. Huber. 2003. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor κB activation by tumor necrosis factor. *J. Exp. Med.* 198:1959–1964.
- Reiley, W., M. Zhang, and S.–C. Sun. 2004. Tumor suppressor negatively regulates JNK signaling pathway downstream of TNFR members. *J. Biol. Chem.* 279:55161–55167.
- Yoshida, H., H. Jono, H. Kai, and J.D. Li. 2005. The tumor suppressor CYLD acts as a negative regulator for toll–like receptor 2 signaling via negative cross–talk with TRAF6 and TRAF7. *J. Biol. Chem.* 280:41111–41121.
- Massoumi, R., K. Chmielarska, K. Hennecke, A. Pfeifer, and R. Fassler. 2006. Cyld inhibits tumor cell proliferation by blocking bcl–3–dependent NF– κB signaling. *Cell.* 125:665–677.

13. Zhang, J., B. Stirling, S.T. Temmerman, C.A. Ma, I.J. Fuss, J.M. Derry, and A. Jain. 2006. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. *J. Clin. Invest.* 116:3042–3049.
14. Lin, X., and D. Wang. 2004. The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling. *Semin. Immunol.* 16:429–435.
15. Hacker, H., and M. Karin. 2006. Regulation and function of IKK and IKK-related kinases. *Sci. STKE.* doi:10.1126/stke.3572006re13.
16. Senfleben, U., Y. Cao, G. Xiao, G. Kraehn, F. Greten, Y. Chen, Y. Hu, A. Fong, S.-C. Sun, and M. Karin. 2001. Activation of IKK α of a second, evolutionary conserved, NF- κ B signaling pathway. *Science.* 293:1495–1499.
17. Xiao, G., E.W. Harhaj, and S.C. Sun. 2001. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. *Mol. Cell.* 7:401–409.
18. Liu, H.H., M. Xie, M.D. Schneider, and Z.J. Chen. 2006. Essential role of TAK1 in thymocyte development and activation. *Proc. Natl. Acad. Sci. USA.* 103:11677–11682.
19. Sato, S., H. Sanjo, T. Tsujimura, J. Ninomiya-Tsuji, M. Yamamoto, T. Kawai, O. Takeuchi, and S. Akira. 2006. TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. *Int. Immunol.* 18:1405–1411.
20. Wan, Y.Y., H. Chi, M. Xie, M.D. Schneider, and R.A. Flavell. 2006. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. *Nat. Immunol.* 7:851–858.
21. Wang, C., L. Deng, M. Hong, G.R. Akkaraju, J.-I. Inoue, and Z.J. Chen. 2001. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. *Nature.* 412:346–351.
22. Ninomiya-Tsuji, J., K. Kishimoto, A. Hiyama, J. Inoue, Z. Cao, and K. Matsumoto. 1999. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. *Nature.* 398:252–256.
23. Dohi, T., K. Fujihashi, P.D. Rennert, K. Iwatani, H. Kiyono, and J.R. McGhee. 1999. Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. *J. Exp. Med.* 189:1169–1180.
24. Sartor, R.B. 2006. Mechanisms of disease: pathogenesis of Chron's disease and ulcerative colitis. *Nat. Clin. Pract. Gastroenterol. Hepatol.* 3:390–407.
25. Niessner, M., and B.A. Volk. 1995. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). *Clin. Exp. Immunol.* 101:428–435.
26. Melgar, S., M.M. Yeung, A. Bas, G. Forsberg, O. Suhr, A. Oberg, S. Hammarstrom, A. Danielsson, and M.L. Hammarstrom. 2003. Overexpression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. *Clin. Exp. Immunol.* 134:127–137.
27. Brenner, O., D. Levanon, V. Negreanu, O. Golubkov, O. Fainaru, E. Woolf, and Y. Groner. 2004. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. *Proc. Natl. Acad. Sci. USA.* 101:16016–16021.
28. Podolsky, D.K. 2002. Inflammatory bowel disease. *N. Engl. J. Med.* 347:417–429.
29. Molina, T.J., K. Kishihara, D.P. Siderovski, W. van Ewijk, A. Narendran, E. Timms, A. Wakeham, C.J. Paige, K.U. Hartmann, A. Veillette, et al. 1992. Profound block in thymocyte development in mice lacking p56lck. *Nature.* 357:161–164.
30. Lombardi, L., P. Ciana, C. Cappellini, D. Trecca, L. Guerrini, A. Migliazza, A.T. Maiolo, and A. Neri. 1995. Structural and functional characterization of the promoter regions of the NFKB2 gene. *Nucleic Acids Res.* 23:2328–2336.
31. Bren, G.D., N.J. Solan, H. Miyoshi, K.N. Pennington, L.J. Pobst, and C.V. Paya. 2001. Transcription of the RelB gene is regulated by NF-kappaB. *Oncogene.* 20:7722–7733.
32. Thiefes, A., A. Wolf, A. Doerrie, G.A. Grassl, K. Matsumoto, I. Autenrieth, E. Bohn, H. Sakurai, R. Niedenthal, K. Resch, and M. Kracht. 2006. The *Yersinia enterocolitica* effector YopP inhibits host cell signalling by inactivating the protein kinase TAK1 in the IL-1 signalling pathway. *EMBO Rep.* 7:838–844.
33. Sato, S., H. Sanjo, K. Takeda, J. Ninomiya-Tsuji, M. Yamamoto, T. Kawai, K. Matsumoto, O. Takeuchi, and S. Akira. 2005. Essential function for the kinase TAK1 in innate and adaptive immune responses. *Nat. Immunol.* 6:1087–1095.
34. Shim, J.H., C. Xiao, A.E. Paschal, S.T. Bailey, P. Rao, M.S. Hayden, K.Y. Lee, C. Bussey, M. Steckel, N. Tanaka, et al. 2005. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. *Genes Dev.* 19:2668–2681.
35. Omori, E., K. Matsumoto, H. Sanjo, S. Sato, S. Akira, R.C. Smart, and J. Ninomiya-Tsuji. 2006. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. *J. Biol. Chem.* 281:19610–19617.
36. Lee, E.G., D.L. Boone, S. Chai, S.L. Libby, M. Chien, J.P. Lodolce, and A. Ma. 2000. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. *Science.* 289:2350–2354.
37. Boone, D.L., E.E. Turer, E.G. Lee, R.C. Ahmad, M.T. Wheeler, C. Tsui, P. Hurlley, M. Chien, S. Chai, O. Hitotsumatsu, et al. 2004. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. *Nat. Immunol.* 5:1052–1060.
38. Wertz, I.E., K.M. O'Rourke, H. Zhou, M. Eby, L. Aravind, S. Seshagiri, P.Wu, C. Wiesmann, R. Baker, D.L. Boone, et al. 2004. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. *Nature.* 430:694–699.
39. Strober, W., P.J. Murray, A. Kitani, and T. Watanabe. 2006. Signalling pathways and molecular interactions of NOD1 and NOD2. *Nat. Rev. Immunol.* 6:9–20.
40. Hugot, J.P., M. Chamaillard, H. Zouali, S. Lesage, J.P. Cezard, J. Belaiche, S. Almer, C. Tysk, C.A. O'Morain, M. Gassull, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature.* 411:599–603.
41. Ogura, Y., D.K. Bonen, N. Inohara, D.L. Nicolae, F.F. Chen, R. Ramos, H. Britton, T. Moran, R. Karaliuskas, R.H. Duerr, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature.* 411:603–606.
42. Pauleau, A.L., and P.J. Murray. 2003. Role of nod2 in the response of macrophages to toll-like receptor agonists. *Mol. Cell. Biol.* 23:7531–7539.
43. Kobayashi, K.S., M. Chamaillard, Y. Ogura, O. Henegariu, N. Inohara, G. Nunez, and R.A. Flavell. 2005. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. *Science.* 307:731–734.
44. Maeda, S., L.C. Hsu, H. Liu, L.A. Bankston, M. Limura, M.F. Kagnoff, L. Eckmann, and M. Karin. 2005. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. *Science.* 307:734–738.
45. Costello, C.M., N. Mah, R. Hasler, P. Rosenstiel, G.H. Waetzig, A. Hahn, T. Lu, Y. Gurbuz, S. Nikolaus, M. Albrecht, J. Hampe, R. Lucius, G. Kloppel, H. Eickhoff, H. Lehrach, T. Lengauer, and S. Schreiber. 2005. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. *PLoS Med.* 2:e199.
46. Shibuya, H., K. Yamaguchi, K. Shirakabe, A. Tonegawa, Y. Gotoh, N. Ueno, K. Irie, E. Nishida, and K. Matsumoto. 1996. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. *Science.* 272:1179–1182.
47. Waterfield, M., J. Wei, W. Reiley, M.Y. Zhang, and S.-C. Sun. 2004. IKKb Is an essential component of the Tpl2 signaling pathway. *Mol. Cell. Biol.* 24:6040–6048.
48. Reiley, W., M. Zhang, X. Wu, E. Graner, and S.-C. Sun. 2005. Regulation of the deubiquitinating enzyme CYLD by IKKg-dependent phosphorylation. *Mol. Cell. Biol.* 25:3886–3895.
49. Williams, K.L., C.R. Fuller, L.A. Dieleman, C.M. DaCosta, K.M. Haldeman, R.B. Sartor, and P.K. Lund. 2001. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. *Gastroenterology.* 120:925–937.
50. Uhlik, M., L. Good, G. Xiao, E.W. Harhaj, E. Zandi, M. Karin, and S.-C. Sun. 1998. NF-kappaB-inducing kinase and IkappaB kinase participate in human T-cell leukemia virus I Tax-mediated NF-kappaB activation. *J. Biol. Chem.* 273:21132–21136.
51. Sun, S.-C., P.A. Ganchi, C. Beraud, D.W. Ballard, and W.C. Greene. 1994. Autoregulation of the NF-kappaB transactivator Rel A (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. *Proc. Natl. Acad. Sci. USA.* 91:1346–1350.